MOTS-c storage and shelf life: how to keep it stable

Last updated 2026-07-24

How should MOTS-c be stored before it's reconstituted?

Lyophilized (freeze-dried) MOTS-c, the form it ships in as a vial of white or off-white powder, is the most stable version of the peptide. No published study has run a formal shelf-life assay specifically on synthetic MOTS-c powder under different temperatures, so the storage advice you'll see from compounding pharmacies and peptide vendors is extrapolated from general peptide chemistry, not from MOTS-c-specific data. That's worth being upfront about. The standard practice, consistent across compounded peptide handling generally, is to keep unreconstituted lyophilized powder in a freezer (around -4°F to 14°F, or -20°C to -10°C) for long-term storage, or in a refrigerator (36°F to 46°F, 2°C to 8°C) if it will be used within a few months. Powder form is far more resistant to degradation than liquid, because water is the main driver of peptide bond hydrolysis and bacterial growth. Keep the vial in its original box or wrapped to block light. Peptides are sensitive to UV and even ambient light exposure over time, which can drive oxidation of certain amino acid side chains. Humidity is the other enemy: don't store vials in a bathroom cabinet or anywhere with temperature swings and moisture, like a garage fridge that gets opened constantly. If you're sourcing MOTS-c, the mots-c peptide buy guide covers what separates a pharmacy that ships powder cold-chained and properly sealed from one that doesn't bother.

How long does reconstituted MOTS-c last in the fridge?

Once MOTS-c powder is mixed with bacteriostatic water, most compounding pharmacies and clinical peptide protocols suggest a working window of about 4 to 8 weeks under refrigeration (36°F to 46°F). Some vendors claim longer, up to a few months, but that's a house policy, not a number backed by a published stability study on this specific peptide. Bacteriostatic water contains 0.9% benzyl alcohol, which suppresses bacterial growth in the vial across multiple draws. It does not prevent chemical degradation of the peptide itself. So even in a bacteriostatic solution, the countdown that matters most is chemical stability, not contamination risk, assuming you're using sterile technique. A few practical signs the reconstituted solution has gone bad: visible cloudiness, discoloration (a color shift from clear to yellow or amber), or particulate matter floating in the vial. If you see any of those, discard it. Don't try to filter it out or assume it's fine. This timeline is shorter than the multi-month or multi-year windows the research literature discusses for lyophilized powder in rodent and cell studies, where MOTS-c is typically prepared fresh or from freshly reconstituted stock right before dosing ^[1][2]. The practical shelf life for a home-stored vial is a compounding and handling question, not something the mechanistic papers address.

Can you freeze reconstituted MOTS-c?

Generally, no, not for routine storage between doses. Freezing a reconstituted peptide solution and then thawing it repeatedly is one of the more reliable ways to degrade it. Ice crystal formation during freezing can physically disrupt peptide structure, and each freeze-thaw cycle adds cumulative damage. If a pharmacy or lab needs to bank a reconstituted aliquot for months, the standard approach in research settings is to freeze it once, in single-use aliquots, at -4°F (-20°C) or colder, and never refreeze a thawed aliquot. That's how researchers handle peptide stocks for repeated animal dosing over a study period, splitting one batch into many small tubes so each one only gets thawed once. For a personal-use vial you're drawing from every day or every few days, that single-thaw approach isn't practical. Refrigeration, not freezing, is the standard for a vial in active use. If you truly won't use a reconstituted vial again for months, aliquoting into smaller single-dose portions and freezing those separately is more sensible than freezing and re-thawing the whole vial repeatedly.

What temperature actually destroys MOTS-c?

Room temperature, especially sustained warm room temperature, is the fastest way to shorten a peptide's usable life. Left on a counter at 68°F to 77°F (20°C to 25°C), most reconstituted peptides show measurably faster degradation within days to a couple of weeks compared to refrigerated storage. Heat accelerates hydrolysis and oxidation reactions that break peptide bonds and modify amino acid side chains. This is general peptide chemistry, not a MOTS-c-specific finding, since no public stability trial has published exact degradation curves for MOTS-c at different temperatures. But the mechanism (a 39-amino-acid peptide with standard peptide bonds) doesn't give any reason to think MOTS-c is unusually heat-stable compared to other research peptides. A car glovebox, a gym bag left in a hot car, a bathroom shelf near a shower: all of these subject the vial to temperature swings that add up. If you travel with a reconstituted vial, an insulated cooler bag with an ice pack keeps it in range for a day or two. Don't pack it in checked luggage on a flight, where cargo hold temperatures are unpredictable and sometimes near freezing.

Does light exposure degrade MOTS-c?

Yes, prolonged light exposure, particularly UV and bright ambient light, is a known contributor to oxidative degradation in peptides generally. Vials typically ship in amber glass or in a light-blocking outer box specifically to limit this. The practical fix is simple: keep the vial in its original packaging in the fridge, in a drawer or the back of the shelf rather than the door (which gets more light and bigger temperature swings every time it's opened) and out of direct sunlight during the reconstitution and injection process itself. A few seconds of ambient light while you draw a dose isn't going to ruin a vial. Weeks of sitting on a windowsill will accelerate the problem.

How do you know if MOTS-c has gone bad?

Look for cloudiness, a color change, or visible particles or clumps in the solution. Properly reconstituted MOTS-c should be a clear, colorless liquid. Any haziness or floating debris means the peptide has likely aggregated or degraded, and the vial should be discarded rather than used. A less visible but real problem is potency loss without any obvious appearance change. Peptides can lose activity through slow degradation pathways that don't turn the solution cloudy or discolored. This is the harder failure mode to catch at home, since there's no color-change test for it. It's part of why sticking to the conservative refrigerated-use window (4 to 8 weeks) matters more than waiting for visible signs of spoilage. If you notice the peptide seems to be having less effect than earlier in a cycle, and the vial is more than a few weeks old, degradation is a reasonable first suspicion, though it's impossible to confirm without lab testing (which almost no individual user has access to). See mots-c side effects for a broader look at what changes in response might mean, and what doesn't.

What's the actual shelf life of unopened, unreconstituted MOTS-c?

This is where the honest answer is: nobody has published a rigorous, MOTS-c-specific stability study covering multi-year storage at defined temperatures. What exists is standard peptide industry practice, which treats lyophilized powder as stable for roughly 2 to 3 years when kept frozen and unopened, and shorter (often 6 months to a year) if kept refrigerated rather than frozen. Those numbers come from general peptide-industry handling norms and manufacturer/compounder guidance, not from a controlled MOTS-c degradation study published in a peer-reviewed journal. The mechanistic and animal-model papers on MOTS-c, including the original Cell Metabolism paper describing its role in metabolic homeostasis ^[2] and the 2018 Cell Metabolism paper on its nuclear translocation function ^[3], don't report long-term storage stability data because that's not what those studies were designed to measure. They're mechanism papers, not shelf-life papers. So when a vendor tells you MOTS-c powder is good for 2 years frozen, that's an industry convention borrowed from peptide chemistry broadly, applied to this molecule by analogy. It's probably a reasonable estimate. It is not a cited, MOTS-c-specific finding.

Does bacteriostatic water storage affect shelf life?

Bacteriostatic water itself, once opened, is typically good for about 28 days per most compounding pharmacy guidance, a convention borrowed from multi-dose vial standards used broadly in injectable medicine. After that, even if it looks fine, the benzyl alcohol preservative's antimicrobial effectiveness in an opened, repeatedly-punctured vial is less certain. Practically, this means your bacteriostatic water vial may reach its own use-by point before your MOTS-c vial does, especially if you're using the same water vial to reconstitute multiple peptide vials over time. Keep track of both open-dates separately. Label the bacteriostatic water vial with the date you first opened it, more than the MOTS-c vial.

How does storage differ for research use versus at-home use?

In lab settings, MOTS-c is typically prepared fresh for each dosing session or study, or aliquoted into single-use frozen portions specifically to avoid the freeze-thaw and room-temperature exposure problems described above. Rodent studies dosing MOTS-c for insulin resistance and obesity outcomes ^[2], or gestational diabetes models ^[4], or muscle atrophy protocols ^[5], are working with controlled cold-chain handling and short windows between preparation and injection. That's a very different logistics picture than someone storing a personal-use vial in a home fridge for six weeks. The gap between "how researchers handle it in a lab" and "how a person handles it at home" is real, and it's one reason storage advice from a compounding pharmacy (built around home-use realities: a normal fridge, a normal schedule, imperfect conditions) is more useful for individual users than trying to replicate lab protocol at home.

What does the research evidence on MOTS-c actually cover, versus storage?

It's worth separating two very different bodies of information: what's known about MOTS-c biology, and what's known about how to store a vial of it. The storage guidance above is general peptide chemistry and pharmacy practice. The biology is where the actual research volume sits, and it's almost entirely preclinical. The original 2015 Cell Metabolism paper described MOTS-c as promoting metabolic homeostasis and reducing obesity and insulin resistance in mouse models ^[2]. The 2018 follow-up in the same journal showed MOTS-c translocates to the nucleus under metabolic stress and regulates nuclear gene expression, a mechanism distinct from typical peptide hormone signaling ^[3]. A 2023 Frontiers in Endocrinology review calls it "a promising mitochondrial-derived peptide for therapeutic exploitation" ^[1], language that signals early-stage interest rather than clinical validation. Since then, the published work has branched into rodent and cell-culture studies across many tissues: gestational diabetes models ^[4], diabetic cardiomyopathy ^[6], ovarian cancer cell lines ^[7], lung ischemia-reperfusion injury ^[8], pulmonary fibrosis ^[9], osteoarthritis cartilage models ^[10], bone metabolism ^[11], skeletal muscle atrophy from immobilization ^[5], and even HBV antiviral activity in a 2024 Gut paper ^[12]. This is a broad, genuinely interesting research footprint. It is also, without exception in the sources reviewed here, animal or cell-culture work. No large human clinical trial establishing safety or efficacy in people has been published as of this writing. The "exercise mimetic" framing you'll see in marketing comes from real biology: a 2021 review in Biochimica et Biophysica Acta discusses mitochondrial-derived peptides in the context of exercise physiology ^[13], and a 2022 Diabetes & Metabolism Journal paper covers exercise, mitohormesis, and MOTS-c specifically ^[14]. A 2025 Scientific Reports study found MOTS-c mimicked exercise-associated pathways to reduce diabetic liver fibrosis markers in a mouse model ^[15]. These are real, specific, interesting findings. They are not evidence that a self-administered peptide reproduces the systemic effects of a training program in a human body. That's a marketing leap the primary literature doesn't make. For dosing specifics people ask about once they've read the underlying studies, see mots-c dosage.

Is there regulatory guidance covering how MOTS-c should be handled?

MOTS-c is not an FDA-approved drug. A search of Drugs@FDA, the FDA's database of approved drug products, does not list MOTS-c ^[16]. It's synthesized and sold as a research or compounded product, which puts its handling under a different regulatory framework than an approved medication with FDA-mandated storage instructions on the label. Compounding pharmacies that prepare MOTS-c for patient use operate under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a) ^[17]. The FDA maintains lists of bulk drug substances that can lawfully be used in compounding under these sections, found in 21 CFR 216.23 for 503A ^[18] and 21 CFR 216.24 for 503B ^[19]. Whether a given peptide appears on these lists, or on FDA's separately published list of nominated bulk substances under review ^[20], changes the legal footing for a pharmacy compounding it, and that status can shift over time as FDA updates its lists. None of this regulatory framework specifies a storage temperature or shelf life for MOTS-c specifically. It governs who can legally prepare and dispense it, not how a patient should store the vial at home. That's why storage guidance in practice comes from the dispensing pharmacy's own stability protocols, layered onto general peptide chemistry, rather than from a government-mandated shelf-life standard.

What should you actually do with a MOTS-c vial at home?

Keep unreconstituted powder frozen or refrigerated, in its original light-blocking packaging, until you're ready to mix it. Reconstitute with bacteriostatic water using sterile technique. Refrigerate the mixed solution at 36°F to 46°F, don't freeze it once it's liquid, and plan to use it within 4 to 8 weeks. Track two dates: when you opened the bacteriostatic water, and when you reconstituted the peptide, since the water's own use-by window (about 28 days) may arrive before the peptide's does. Discard the vial if you see cloudiness, discoloration, or particulates, no exceptions. Don't leave the vial out at room temperature for extended periods, don't pack it in checked airline luggage, and don't refreeze a vial that's already been thawed once. MOTS-c Co doesn't compound or manufacture peptides. The provider-reviewed route, where a clinician evaluates whether MOTS-c fits your situation and a licensed pharmacy partner handles compounding, sterility testing, and cold-chain shipping, removes most of the guesswork described in this article, since a legitimate compounding pharmacy is already accounting for stability in how it ships and what expiration date it puts on the label. If you're trying to figure out sourcing before you get to storage, the mots-c peptide buy guide is the place to start, and mots-c peptide injection covers the reconstitution and injection technique itself.

Frequently asked questions

How long does MOTS-c last once reconstituted?

Most compounding pharmacy guidance suggests 4 to 8 weeks when refrigerated at 36°F to 46°F. This is a general peptide-handling convention, not a figure from a published MOTS-c-specific stability study. Discard the vial sooner if you see cloudiness, discoloration, or particulates, regardless of how many weeks have passed.

Can MOTS-c be stored at room temperature?

Briefly, yes (during travel or while drawing a dose), but not for routine storage. Sustained room temperature (68°F to 77°F) accelerates peptide degradation through hydrolysis and oxidation. Refrigeration is the standard for a reconstituted vial in active use; freezing is standard only for unopened lyophilized powder or single-use frozen aliquots.

Should MOTS-c be frozen or refrigerated?

Unreconstituted lyophilized powder: freezer for long-term storage, fridge if using within a few months. Once mixed with bacteriostatic water: refrigerate, don't freeze. Freezing a liquid solution and thawing it repeatedly can physically damage the peptide through ice crystal formation, so freeze only single-use aliquots you won't refreeze.

How can you tell if MOTS-c has degraded or gone bad?

Check for cloudiness, a color shift away from clear/colorless, or visible particles or clumps in the vial. Any of these means discard it. Potency loss without visible change is also possible and harder to detect at home, which is why sticking to conservative storage windows matters more than waiting for visible spoilage signs.

Does MOTS-c need to be protected from light?

Yes. Peptides generally are sensitive to UV and prolonged ambient light exposure, which can drive oxidative degradation. Keep the vial in its original box or light-blocking packaging, store it in the back of the fridge rather than the door, and avoid leaving it on a windowsill or in direct sun.

How long does bacteriostatic water last once opened?

Roughly 28 days per common compounding pharmacy convention, similar to multi-dose vial standards used across injectable medicine generally. Track the open-date on the bacteriostatic water vial separately from your MOTS-c reconstitution date, since the water may need replacing before the peptide vial's own use-by window is up.

Is there a published shelf-life study specifically for MOTS-c?

No. No peer-reviewed stability study has established exact degradation timelines for synthetic MOTS-c powder or reconstituted solution at defined temperatures. Storage guidance in practice comes from general peptide chemistry and compounding pharmacy convention, applied to MOTS-c by analogy, not from a MOTS-c-specific published trial.

Can you travel with MOTS-c?

Yes, with care. Use an insulated cooler bag with an ice pack to keep the vial cold for a day or two. Avoid checked airline luggage, where cargo hold temperatures are unpredictable and sometimes near freezing. Don't leave the vial in a hot car or a bag exposed to direct sun for extended periods.

What happens if MOTS-c freezes and thaws multiple times?

Repeated freeze-thaw cycles are one of the more reliable ways to degrade a reconstituted peptide, since ice crystal formation can physically disrupt its structure with each cycle. If you need frozen storage, split the solution into single-use aliquots up front so each one is thawed exactly once, never refrozen.

Is MOTS-c actually 'exercise in a pill' as some sellers claim?

That framing overstates the evidence. Published work links MOTS-c to mitohormesis and exercise-responsive pathways ^[13][14], and a 2025 study found it mimicked exercise-associated effects on liver fibrosis markers in mice ^[15]. These are real, specific rodent findings, not proof that a peptide reproduces training's systemic effects in humans.

Is MOTS-c FDA-approved, and does that affect storage guidance?

No. MOTS-c does not appear in Drugs@FDA, the FDA's approved drug products database ^[16]. It lacks an FDA-mandated label with official storage instructions. Practical storage guidance instead comes from compounding pharmacy stability protocols and general peptide chemistry, not from a government-set shelf-life standard specific to this molecule.

Does the research on MOTS-c's biological effects apply to how you store it?

No, these are separate questions. Studies on MOTS-c's role in insulin resistance ^[2], nuclear gene regulation ^[3], or muscle atrophy ^[5] are mechanism and outcome studies in rodent or cell models, not stability trials. None of the cited research literature reports shelf-life or degradation-rate data for the compound.

Sources

1. PubMed, Frontiers in Endocrinology 2023 (PMID 36761202): 2023 review describes MOTS-c as a promising mitochondrial-derived peptide for therapeutic exploitation
2. PubMed, Cell Metabolism 2015 (PMID 25738459): Original study showing MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance in mouse models
3. PubMed, Cell Metabolism 2018 (PMID 29983246): MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress
4. PubMed, Pharmacological Research 2022 (PMID 34798268): MOTS-c relieves hyperglycemia and insulin resistance in a gestational diabetes mellitus model
5. PubMed, American Journal of Physiology-Endocrinology and Metabolism 2024 (PMID 38170165): MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration in an animal model
6. PubMed, Cardiovascular Drugs and Therapy 2025 (PMID 40172798): 2025 review examines MOTS-c's proposed role in diabetic cardiomyopathy
7. PubMed, Advanced Science 2024 (PMID 39321430): MOTS-c suppresses ovarian cancer progression via USP7-mediated LARS1 deubiquitination in cell models
8. PubMed, Redox Biology 2025 (PMID 40403491): MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-dependent nuclear translocation
9. PubMed, Mitochondrion 2023 (PMID 37307934): MOTS-c identified as a potential anti-pulmonary fibrosis factor derived by mitochondria
10. PubMed, Free Radical Biology & Medicine 2025 (PMID 41043625): MOTS-c attenuates mitochondrial dysfunction, pyroptosis, and cartilage degradation in an osteoarthritis model
11. PubMed, Frontiers in Physiology 2023 (PMID 37200834): Review of MOTS-c's role in the regulation of bone metabolism
12. PubMed, Gut 2024 (PMID 37788894): MOTS-c shows an antiviral role during HBV infection via mitochondrial remodelling in a 2024 study
13. PubMed, Biochimica et Biophysica Acta - General Subjects 2021 (PMID 34520826): Review covers the relationship between mitochondrial-derived peptides and exercise
14. PubMed, Diabetes & Metabolism Journal 2022 (PMID 35656563): Review covers exercise, mitohormesis, and MOTS-c as a mitochondrial ORF product
15. PubMed, Scientific Reports 2025 (PMID 40425777): MOTS-c mimics exercise-associated pathways to combat diabetic liver fibrosis in a mouse model via Keap1-Nrf2-Smad2/3
16. FDA, Drugs@FDA approved drug products database: MOTS-c does not appear as an FDA-approved drug product
17. Cornell Legal Information Institute, 21 U.S.C. 353a: Section 503A of the FD&C Act governs pharmacy compounding standards
18. eCFR, 21 CFR 216.23: 21 CFR 216.23 lists bulk drug substances that may be used in 503A compounding
19. eCFR, 21 CFR 216.24: 21 CFR 216.24 lists bulk drug substances that may be used in 503B outsourcing facility compounding
20. FDA, bulk drug substances nominated for use in compounding (current list): FDA maintains a current list of bulk drug substances nominated and under review for compounding use